SelenBio on Netcapital

antibacterial technology for a wide variety of use cases

Raise to date: $31,264

Reporting Date: 11/10/2019

Key Stats

Minimum Raise

$10,000

Maximum Raise

$1,070,000

Likelihood of Max Unlikely
Start Date

10/03/2019

Stop Date

01/31/2020

Days Remaining

81

Security Type

Common Stock

Investment Minimum

$4

Deal Type

No Review


Investment Summary

Status

Active

# of Investors

Not Known

% of Minimum Raised

313%

% of Maximum Raised

3%

Dollars Per Day to Reach Max

$12,824

DPD* Committed

$823

DPD* Category

$0

DPD* All Companies

$1,359

Kingscrowd Momentum

$31,264

Total Dollars Raised

Commitments

Weekly Commitments ($)
Aggregate Commitments ($)

SEC Filing Data from Kingscrowd

SelenBio, a biotechnology company with a post-money valuation of $20.7 million, is raising funds on NetCapital. The company develops an antibacterial technology that prevents the formation of biofilm in dental, medical, industrial, and consumer applications. SelenBio uses a unique selenium-based compound, SELDOX, to keep the applications infection-free. The company was founded by Kenny Gallagher and Karl Doenges. The proceeds of the current crowdfunding round, with a minimum target of $10,000 and a maximum target of $1,070,000, will be used for research & development, operations, completion of current projects, sales & marketing, and compensation for managers. SelenBio is working on multiple projects with excellent traction and has already received the FDA approval for SELDOX.

INVEST NOW